scholarly journals Use of dornase alfa in cystic fibrosis: an Audit of Italian specialists

2021 ◽  
Author(s):  
Sonia Volpi ◽  
Vincenzo Carnovale ◽  
Carla Colombo ◽  
Valeria Raia ◽  
Francesco Blasi ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Lung Function ◽  
Delphi Method ◽  
Therapeutic Use ◽  
Long Term Outcomes ◽  
Progressive Decline ◽  
Dornase Alfa ◽  
Modified Delphi ◽  
Appropriate Prescribing

Background: The goal of mucoactive therapies in cystic fibrosis (CF) is to enhance sputum clearance and to reduce a progressive decline in lung function over the patient’s lifetime. We aimed to investigate the level of consensus among specialists from Italian CF Centers on appropriateness of therapeutic use of dornase alfa (rhDNase) for CF patients. Method: A consensus on appropriate prescribing in CF mucoactive agents was appraised by an online Delphi method, based on a panel of 27 pulmonologists, coordinated by a Scientific Committee of six experts in medical care of patients with CF. Results: Full or very high consensus was reached on several issues related to therapeutic use of dornase alfa for CF patients in clinical practice. Conclusions: Modified Delphi method was used to define the most appropriate use of dornase alfa in routine CF to improve lung function and long-term outcomes in patients, in agreement with international guidelines on CF management.

PO-1019: Long term outcomes and lung function evolution of primary lung tumors treated with Cyberknife SABR

2020 ◽  
Vol 152 ◽  
pp. S543-S544
Author(s):  
F. Sacino ◽  
N. Jansen ◽  
C. Mievis ◽  
L. Seidel ◽  
S. Cucchiaro ◽  
...  
Keyword(s):  
Lung Function ◽  
Lung Tumors ◽  
Long Term Outcomes ◽  
Primary Lung Tumors

scholarly journals Poor recovery from cystic fibrosis pulmonary exacerbations is associated with poor long-term outcomes

2017 ◽  
Vol 52 (10) ◽  
pp. 1268-1275 ◽  
Author(s):  
Don B. Sanders ◽  
Qianqian Zhao ◽  
Zhanhai Li ◽  
Philip M. Farrell
Keyword(s):  
Cystic Fibrosis ◽  
Long Term Outcomes ◽  
Poor Recovery ◽  
Pulmonary Exacerbations

scholarly journals Impact of Long-Term Tiotropium Bromide Therapy on Annual Lung Function Decline in Adult Patients with Cystic Fibrosis

PLoS ONE ◽  
2016 ◽  
Vol 11 (6) ◽  
pp. e0158193 ◽  
Author(s):  
Claudia Brandt ◽  
Anja Thronicke ◽  
Jobst F. Roehmel ◽  
Alexander Krannich ◽  
Doris Staab ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Lung Function ◽  
Adult Patients ◽  
Tiotropium Bromide ◽  
Lung Function Decline ◽  
Bromide Therapy

Presence of mucus plugging is predictive of long term lung function in children with cystic fibrosis

2017 ◽  
Author(s):  
Lidija Turkovic ◽  
Daan Caudri ◽  
Tim Rosenow ◽  
Graham Hall ◽  
Stephen Stick
Keyword(s):  
Cystic Fibrosis ◽  
Lung Function

Long-term azithromycin may improve lung function in children with cystic fibrosis

The Lancet ◽  
1998 ◽  
Vol 351 (9100) ◽  
pp. 420 ◽  
Author(s):  
Adam Jaffé ◽  
Jackie Francis ◽  
Mark Rosenthal ◽  
Andrew Bush
Keyword(s):  
Cystic Fibrosis ◽  
Lung Function ◽  
Improve Lung Function

scholarly journals Management of chronic Pseudomonas aeruginosa infection with inhaled levofloxacin in people with cystic fibrosis

2021 ◽  
Author(s):  
J Stuart Elborn ◽  
Patrick A Flume ◽  
Donald R Van Devanter ◽  
Claudio Procaccianti
Keyword(s):  
Quality Of Life ◽  
Cystic Fibrosis ◽  
Pseudomonas Aeruginosa ◽  
Lung Function ◽  
Standard Care ◽  
Bacterial Infections ◽  
Pulmonary Infections ◽  
Pseudomonas Aeruginosa Infection

People with cystic fibrosis (CF) are highly susceptible to bacterial infections of the airways. By adulthood, chronic Pseudomonas aeruginosa ( Pa) is the most prevalent infective organism and is difficult to eradicate owing to its adaptation to the CF lung microenvironment. Long-term suppressive treatment with inhaled antimicrobials is the standard care for reducing exacerbation frequency, improving quality of life and increasing measures of lung function. Levofloxacin (a fluoroquinolone antimicrobial) has been approved as an inhaled solution in Europe and Canada, for the treatment of adults with CF with chronic P. aeruginosa pulmonary infections. Here, we review the clinical principles relating to the use of inhaled antimicrobials and inhaled levofloxacin for the management of P. aeruginosa infections in patients with CF.

Long-term outcomes and clinical worsening in cystic fibrosis patients with at least one residual function mutation

2018 ◽  
Author(s):  
Andrea Gramegna ◽  
Martina Contarini ◽  
Stefano Aliberti ◽  
Giovanni Sotgiu ◽  
Manuela Seia ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Long Term Outcomes ◽  
Residual Function ◽  
Clinical Worsening
Sign in / Sign up

Export Citation Format

Share Document